Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23778311 | 1.00 | CYP2D6 (0.52) | CYP2D6KDM1ACHRM4ALDH1A1MEN1 | |
| SCHEMBL20066070 | 0.94 | CYP2D6 (0.46) | CYP2D6KDM1ACHRM4ALDH1A1MEN1 | |
| SCHEMBL23375451 | 0.89 | KDM1A (0.55) | CYP2D6KDM1ACHRM4MEN1KMT2A | |
| SCHEMBL23375452 | 0.89 | KDM1A (0.55) | CYP2D6KDM1ACHRM4MEN1KMT2A | |
| SCHEMBL20073962 | 0.85 | CYP2D6 (0.51) | CYP2D6KDM1AALDH1A1MEN1KMT2A | |
| SCHEMBL20073966 | 0.85 | CYP2D6 (0.51) | CYP2D6KDM1AALDH1A1MEN1KMT2A | |
| SCHEMBL28954166 | 0.84 | KDM1A (0.53) | CYP2D6KDM1ACHRM4MEN1KMT2A | |
| SCHEMBL29709538 | 0.82 | ALDH1A1 (0.37) | CYP2D6KDM1AALDH1A1MEN1KMT2A | |
| SCHEMBL20073700 | 0.79 | OPRM1 (0.42) | ALDH1A1MEN1KMT2AADRA1AACACB | |
| SCHEMBL20066001 | 0.78 | CYP2D6 (0.50) | CYP2D6KDM1AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109996792-B | Heterocyclic compounds having activity as modulators of muscarinic M1 and/or M4 receptors in the treatment of CNS diseases and pain | 赫普泰雅治疗有限公司 | 2023-02-17 | — | — | CN | claimed |
| EP-3526207-B1 | HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. | HEPTARES THERAPEUTICS LTD (GB) | 2021-09-08 | — | — | EP | claimed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213034-A1 | SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | CYP2D6 261/4885KDM1A 1427/4885CHRM4 3/4885 |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | CYP2D6 261/4885KDM1A 1427/4885CHRM4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.